Recent Advancements in Proteomics

Systems-wide reasoning leads to a more comprehensive view of the complex signaling transduction pathways that proteins employ in and improves the overall considerate of the complex case supporting the living systems. Over the last two decades, the advancement of high-throughput analytical tools, such as micro-array technologies, able of fastly evaluating thousands of protein-functioning and protein-collaborated events, has agitate the growth of this critical field.

Relevant Conferences:

7th International Conference & Exhibition on Proteomics during October 24-26, 2016 Rome, Italy; 2nd International Conference on Genetic & Protein Engineering during November 14-16, 2016 Atlanta, USA; International Conference & Expo on Molecular & Cancer Biomarkers during September 15-17, 2016 Berlin, Germany; 7th International Conference on Biomarkers and Clinical Research during November 28-30, 2016 Baltimore, USA; 5th International Conference on Computational Systems Biology during August 22-23, 2016 Philadelphia, USA; Gene transcription in yeast: From chromatin to RNA during June 11–16, 2016 Spain; Molecular & developmental biology Conference during June 19–25, 2016, Chania; 18th Bioinformatics & Computational Biology meeting during January 18 -19, 2016, UK; 21st Mass Spectrometry Conference (IMSC 2016) during August 20-26, 2016 Canada; 16th Spectroscopy of Biological Molecules Conference during September 06-10, 2015, Germany.

Proteomics techniques are used to study the protein content and characteristics of biological samples. The major tool of proteomics approaches is mass spectrometry. Mass spectrometry is used to identify proteins and, in conjuction with isotopic labeling, this technique can also determine relative amounts of proteins in 2 or more samples. The proteome is a varied and dynamic repertoire of molecules that in many ways dictates the functional form that is taken by the genome. In medicine, a biomarker is a measurable indicator of the severity or presence of some disease state. More generally a biomarker is anything that can be used as an indicator of a particular disease state or some other physiological state of an organism. Cardiovascular diseases (CVDs) are the major source of global morbidity and death and more people die annually from CVDs than from any other cause.

  • Proteomics and cell immunity
  • Proteomics at pharmaceuticals
  • Proteomics of microbes and infectious diseases
  • Disease biomarkers
  • Cardiovascular and haematological proteomics

Related Conference of Recent Advancements in Proteomics

Recent Advancements in Proteomics Conference Speakers